Stifel Nicolaus Cuts Zoetis (NYSE:ZTS) Price Target to $80.00

Zoetis (NYSE:ZTS) had its price target decreased by Stifel Nicolaus from $85.00 to $80.00 in a research note issued to investors on Thursday morning, MarketBeat.com reports. Stifel Nicolaus currently has a hold rating on the stock.

ZTS has been the topic of several other reports. BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Barclays reduced their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Piper Sandler decreased their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Finally, Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $109.23.

Zoetis Trading Up 3.6%

Shares of Zoetis stock opened at $77.72 on Thursday. The firm has a market cap of $32.12 billion, a price-to-earnings ratio of 12.80, a price-to-earnings-growth ratio of 1.82 and a beta of 0.74. Zoetis has a 52-week low of $71.00 and a 52-week high of $158.30. The company’s 50-day simple moving average is $75.76 and its 200-day simple moving average is $97.33. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same period last year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts anticipate that Zoetis will post 6.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ZTS. J. Stern & Co. LLP increased its stake in Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. Norges Bank acquired a new position in shares of Zoetis during the 4th quarter valued at about $734,425,000. Vanguard Group Inc. grew its holdings in Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Flossbach Von Storch SE acquired a new position in Zoetis during the second quarter worth approximately $302,601,000. Finally, BlackRock Inc. increased its position in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.